The Role of Different Behavioral and Psychosocial Factors in the Context of Pharmaceutical Cognitive Enhancers' Misuse.

Tina Tomažič, Anita Kovačič Čelofiga
Author Information
  1. Tina Tomažič: Faculty of Electrical Engineering and Computer Science, Institute for Media Communications, University of Maribor, 2000 Maribor, Slovenia. ORCID
  2. Anita Kovačič Čelofiga: Faculty of Electrical Engineering and Computer Science, Institute for Media Communications, University of Maribor, 2000 Maribor, Slovenia.

Abstract

In an effort for better memory, greater motivation, and concentration, otherwise healthy individuals use pharmaceutical cognitive enhancers (PCEs), medicines for the treatment of cognitive deficits of patients with various disorders and health problems, to achieve greater productivity, efficiency, and performance. We examined the use of PCEs among 289 students at the Slovenian Faculty of Electrical Engineering and Computer Science in the behavioral and psychosocial context (students' attitudes towards study, parents, health, leisure time, and work). Furthermore, we also addressed the immediate reasons, or the hypothesized connections of behavioral and psychosocial aspects, related to PCE misuse. The study consisted of a structured questionnaire, and chi-squared tests were used. An analysis of student statements revealed differences in students' and parents' attitudes toward good academic grades. In addition, students chose among 17 values related to relationships with parents, friends, partners, careers, study obligations, leisure, hobbies, material goods, appearance, and the future, and assessed their importance. Regardless of the group they belonged to, young people cited the same values among the most important. Good grades and parental opinions have proven to be key factors in the context of PCE abuse. This research was the first study to examine the relation between PCE misuse and the role of different behavioral and psychosocial factors.

Keywords

References

  1. Front Psychol. 2016 Apr 19;7:520 [PMID: 27148128]
  2. Healthcare (Basel). 2022 Jan 18;10(2): [PMID: 35206801]
  3. Wiley Interdiscip Rev Cogn Sci. 2014 Jan;5(1):95-103 [PMID: 26304298]
  4. Clin Pharmacol Ther. 2017 Feb;101(2):170-172 [PMID: 27557349]
  5. BMC Med. 2013 Apr 09;11:102 [PMID: 23570256]
  6. BMC Psychol. 2020 Nov 7;8(1):119 [PMID: 33160397]
  7. Wiley Interdiscip Rev Cogn Sci. 2014 Sep;5(5):533-549 [PMID: 26308743]
  8. Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2129-2139 [PMID: 32141583]
  9. Hastings Cent Rep. 1996 Mar-Apr;26(2):12-8 [PMID: 8722521]
  10. Addict Behav. 2013 Mar;38(3):1643-50 [PMID: 23254212]
  11. Front Psychol. 2016 Mar 01;7:277 [PMID: 26973573]
  12. Int J Neuropsychopharmacol. 2017 Sep 1;20(9):712-720 [PMID: 28525569]
  13. BMC Med. 2020 Nov 24;18(1):351 [PMID: 33228664]
  14. Clin Pharmacol Ther. 2017 Feb;101(2):191-193 [PMID: 27706797]
  15. Brain Sci. 2023 Feb 19;13(2): [PMID: 36831903]
  16. Pharmacopsychiatry. 2014 Jan;47(1):22-8 [PMID: 24222011]
  17. Milbank Q. 2004;82(3):483-506, table of contents [PMID: 15330974]
  18. Addict Behav. 2020 Feb;101:105976 [PMID: 31101387]
  19. Healthcare (Basel). 2022 Feb 10;10(2): [PMID: 35206951]
  20. Philos Ethics Humanit Med. 2019 Apr 25;14(1):7 [PMID: 31023334]
  21. Pharmacopsychiatry. 2011 Mar;44(2):60-6 [PMID: 21161883]
  22. BMC Med. 2016 Jan 22;14:9 [PMID: 26801406]
  23. J Psychoactive Drugs. 2006 Mar;38(1):43-56 [PMID: 16681175]
  24. PLoS One. 2020 Feb 5;15(2):e0227818 [PMID: 32023288]
  25. Br J Clin Pharmacol. 2003 Jan;55(1):39-50 [PMID: 12534639]
  26. J Am Coll Health. 2012;60(3):226-34 [PMID: 22420700]
  27. Philos Ethics Humanit Med. 2012 Jan 13;7:5 [PMID: 22244084]
  28. J Psychoactive Drugs. 2013 Sep-Oct;45(4):360-5 [PMID: 24377176]
  29. Transl Psychiatry. 2021 Nov 8;11(1):574 [PMID: 34750350]
  30. Subst Abuse Treat Prev Policy. 2013 Jun 18;8:23 [PMID: 23777577]
  31. PLoS One. 2014 Oct 30;9(10):e105969 [PMID: 25356917]
  32. Philos Ethics Humanit Med. 2016 Sep 13;11(1):6 [PMID: 27624701]
  33. Nature. 2007 Dec 20;450(7173):1157-9 [PMID: 18097378]
  34. J Am Acad Child Adolesc Psychiatry. 2008 Jun;47(6):700-708 [PMID: 18434918]
  35. J Stud Alcohol Drugs. 2009 Nov;70(6):952-4 [PMID: 19895773]
  36. PLoS One. 2013 Nov 13;8(11):e77967 [PMID: 24236008]
  37. Clin Pharmacol Ther. 2017 Feb;101(2):179-181 [PMID: 27706806]
  38. BMC Med. 2014 Nov 11;12:160 [PMID: 25385407]
  39. Neuropsychiatr Dis Treat. 2007;3(5):627-36 [PMID: 19300592]
  40. Addiction. 2005 Jan;100(1):96-106 [PMID: 15598197]
  41. Nat Rev Neurosci. 2004 May;5(5):421-5 [PMID: 15100724]

Word Cloud

Created with Highcharts 10.0.0studycognitiveamongbehavioralpsychosocialPCEgreaterusepharmaceuticalPCEshealthstudentscontextstudents'attitudesparentsleisurerelatedmisusegradesvaluesfactorsabuseeffortbettermemorymotivationconcentrationotherwisehealthyindividualsenhancersmedicinestreatmentdeficitspatientsvariousdisordersproblemsachieveproductivityefficiencyperformanceexamined289SlovenianFacultyElectricalEngineeringComputerSciencetowardstimeworkFurthermorealsoaddressedimmediatereasonshypothesizedconnectionsaspectsconsistedstructuredquestionnairechi-squaredtestsusedanalysisstudentstatementsrevealeddifferencesparents'towardgoodacademicadditionchose17relationshipsfriendspartnerscareersobligationshobbiesmaterialgoodsappearancefutureassessedimportanceRegardlessgroupbelongedyoungpeoplecitedimportantGoodparentalopinionsprovenkeyresearchfirstexaminerelationroledifferentRoleDifferentBehavioralPsychosocialFactorsContextPharmaceuticalCognitiveEnhancers'Misusenootropicsenhancementsmartdrugssubstance

Similar Articles

Cited By (2)